BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 9495226)

  • 1. Health services use by urban women with or at risk for HIV-1 infection: the HIV Epidemiology Research Study (HERS).
    Solomon L; Stein M; Flynn C; Schuman P; Schoenbaum E; Moore J; Holmberg S; Graham NM
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar; 17(3):253-61. PubMed ID: 9495226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychological resources protect health: 5-year survival and immune function among HIV-infected women from four US cities.
    Ickovics JR; Milan S; Boland R; Schoenbaum E; Schuman P; Vlahov D;
    AIDS; 2006 Sep; 20(14):1851-60. PubMed ID: 16954726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of injection drug use behavior on reported antiretroviral therapy use among women in the HIV Epidemiology Research study: on-site versus referral care.
    Rompalo AM; Shah N; Mayer K; Schuman P; Klein RS; Smith DK; Vlahov D
    J Acquir Immune Defic Syndr; 2001 Sep; 28(1):28-34. PubMed ID: 11579274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuity of medical care and risk of incarceration in HIV-positive and high-risk HIV-negative women.
    Sheu M; Hogan J; Allsworth J; Stein M; Vlahov D; Schoenbaum EE; Schuman P; Gardner L; Flanigan T
    J Womens Health (Larchmt); 2002 Oct; 11(8):743-50. PubMed ID: 12570040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perceived need for and use of mental health services by women living with or at risk of human immunodeficiency virus infection.
    Schuman P; Ohmit SE; Moore J; Schoenbaum E; Boland R; Rompalo A; Solomon L;
    J Am Med Womens Assoc (1972); 2001; 56(1):4-8. PubMed ID: 11213775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of on-site primary care services by HIV-seropositive and seronegative drug users in a methadone maintenance program.
    Selwyn PA; Budner NS; Wasserman WC; Arno PS
    Public Health Rep; 1993; 108(4):492-500. PubMed ID: 8393579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Access to therapy in the Multicenter AIDS Cohort Study, 1989-1992.
    Graham NM; Jacobson LP; Kuo V; Chmiel JS; Morgenstern H; Zucconi SL
    J Clin Epidemiol; 1994 Sep; 47(9):1003-12. PubMed ID: 7730902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten-year trends in CD4 cell counts at HIV and AIDS diagnosis in a London HIV clinic.
    Easterbrook PJ; Yu LM; Goetghebeur E; Boag F; McLean K; Gazzard B
    AIDS; 2000 Mar; 14(5):561-71. PubMed ID: 10780719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study.
    Ickovics JR; Hamburger ME; Vlahov D; Schoenbaum EE; Schuman P; Boland RJ; Moore J;
    JAMA; 2001 Mar; 285(11):1466-74. PubMed ID: 11255423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physical and sexual abuse in women infected with the human immunodeficiency virus: increased illness and health care utilization.
    Liebschutz JM; Feinman G; Sullivan L; Stein M; Samet J
    Arch Intern Med; 2000 Jun; 160(11):1659-64. PubMed ID: 10847259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral blood CD4 + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection.
    Mansharamani NG; Balachandran D; Vernovsky I; Garland R; Koziel H
    Chest; 2000 Sep; 118(3):712-20. PubMed ID: 10988193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV infection in men who have sex with men, New York City Department of Health sexually transmitted disease clinics, 1990-1999: a decade of serosurveillance finds that racial disparities and associations between HIV and gonorrhea persist.
    Torian LV; Makki HA; Menzies IB; Murrill CS; Weisfuse IB
    Sex Transm Dis; 2002 Feb; 29(2):73-8. PubMed ID: 11818891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Racial differences in the use of drug therapy for HIV disease in an urban community.
    Moore RD; Stanton D; Gopalan R; Chaisson RE
    N Engl J Med; 1994 Mar; 330(11):763-8. PubMed ID: 8107743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of mortality among HIV-infected women in Kigali, Rwanda.
    Lindan CP; Allen S; Serufilira A; Lifson AR; Van de Perre P; Chen-Rundle A; Batungwanayo J; Nsengumuremyi F; Bogaerts J; Hulley S
    Ann Intern Med; 1992 Feb; 116(4):320-8. PubMed ID: 1733389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
    J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No seroconversions among steady sex partners of methadone-maintained HIV-1-seropositive injecting drug users in New York City.
    Siddiqui NS; Brown LS; Phillips RY; Vargas O; Makuch RW
    AIDS; 1992 Dec; 6(12):1529-33. PubMed ID: 1492936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between Trichomonas infection and incarceration in HIV-seropositive and at-risk HIV-seronegative women.
    Nijhawan AE; DeLong AK; Celentano DD; Klein RS; Sobel JD; Jamieson DJ; Cu-Uvin S
    Sex Transm Dis; 2011 Dec; 38(12):1094-100. PubMed ID: 22082718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group.
    Stansell JD; Osmond DH; Charlebois E; LaVange L; Wallace JM; Alexander BV; Glassroth J; Kvale PA; Rosen MJ; Reichman LB; Turner JR; Hopewell PC
    Am J Respir Crit Care Med; 1997 Jan; 155(1):60-6. PubMed ID: 9001290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of immunosuppression on health care use by men in the Multicenter AIDS Cohort Study (MACS).
    Zucconi SL; Jacobson LP; Schrager LK; Kass NE; Lave JR; Carson CA; Morgenstern H; Arno PS; Graham NM
    J Acquir Immune Defic Syndr (1988); 1994 Jun; 7(6):607-16. PubMed ID: 7909846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
    ; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
    Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.